相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han et al.
BRITISH JOURNAL OF CANCER (2020)
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
Yang Liu et al.
BIOMEDICINES (2020)
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma
Susan Richter et al.
GENETICS IN MEDICINE (2019)
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Matthew S. Waitkus et al.
CANCER CELL (2018)
Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations
Jing Zhang et al.
ENDOCRINE (2018)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Joakim Crona et al.
ENDOCRINE REVIEWS (2017)
The Krebs Cycle Enzyme Isocitrate Dehydrogenase 3A Couples Mitochondrial Metabolism to Synaptic Transmission
Berrak Ugur et al.
CELL REPORTS (2017)
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Lauren Fishbein et al.
CANCER CELL (2017)
Insulator dysfunction and oncogene activation in IDH mutant gliomas
William A. Flavahan et al.
NATURE (2016)
Isocitrate dehydrogenase mutations in gliomas
Matthew S. Waitkus et al.
NEURO-ONCOLOGY (2016)
IDH mutations in cancer and progress toward development of targeted therapeutics
L. Dang et al.
ANNALS OF ONCOLOGY (2016)
Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era
Suja Pillai et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Metabolic consequences of oncogenic IDH mutations
Seth J. Parker et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation
Chunzhang Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis
Qing-Yun Cheng et al.
SCIENTIFIC REPORTS (2015)
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas
Chunzhang Yang et al.
BLOOD (2013)
Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma
S. R. Galan et al.
CLINICAL ENDOCRINOLOGY (2013)
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Rob A. Cairns et al.
CANCER DISCOVERY (2013)
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp et al.
HUMAN PATHOLOGY (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)